Navigation Links
Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
Date:4/23/2009

Study shows Clonicel(R) and stimulants combined provide greater improvement in symptoms than stimulants alone

DURHAM, N.C., April 23 /PRNewswire/ -- Addrenex Pharmaceuticals, Inc. today announced positive results from a second phase 3 trial of Clonicel demonstrating that the combination of Clonicel with stimulant medications provided statistically significant improvements in attention deficit hyperactivity disorder (ADHD) symptoms compared to stimulant use alone.

Clonicel is the company's lead compound in a pipeline of products that have shown clinical success in alleviating conditions arising from an overactive adrenergic system, the body's control center for regulating stress and a host of other physiologic functions. The Durham-based specialty pharmaceutical company is also developing drugs to treat hypertension, menopausal flushing and potentially insomnia, pain, and migraines.

Based on the positive data from two Phase 3 trials conducted on Clonicel, Addrenex plans to seek approval from the U.S. Food and Drug Administration later this year for Clonicel as both a monotherapy and as an add-on therapy to stimulant medication for children and adolescents with ADHD. The North American rights to market Clonicel are licensed to Sciele Pharma, a Shionogi Company, which is an Atlanta-based specialty pharmaceutical company.

"Our data from the first phase 3 study strongly suggest that Clonicel is an effective therapy for ADHD when used alone, and now we have evidence from a second study that Clonicel also has a complementary effect when used with stimulants," said Moise Khayrallah, Ph.D., CEO of Addrenex Pharmaceuticals. "In children who are not receiving optimal benefit from stimulants such as methylphenidate or amphetamine, Clonicel may provide greater relief than using a stimulant medication alone."

The current study of 200 children with ADHD is the second phase 3 trial in a year
'/>"/>

SOURCE Addrenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
2. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
3. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
4. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
5. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
6. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
7. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
8. Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy
9. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
10. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
11. Strativa Pharmaceuticals Provides Product Pipeline Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... N.C. , March 31, 2015 PGI ... capabilities in North America at ... facility. The anticipated plant expansion is centered ... a need for differentiated products for personal care product ... state-of-the-art printing capabilities with in-line slitting and packaging, will ...
(Date:3/31/2015)... Israel, March 31, 2015  Galmed Pharmaceuticals Ltd. ... company focused on the development and commercialization of ... liver diseases and cholesterol gallstones, today announced financial ... 2014. Fourth Quarter 2014 Highlights: ... a keynote address by Professor Rohit Loomba, MD, ...
(Date:3/31/2015)... , Mar. 27, 2015 Research and Markets ... addition of the "European Laboratory Information System ... by Type (Clinical Pathology Laboratory Information System, Anatomic ... report to their offering. The ... grow at a CAGR of 7.6% from 2014 ...
Breaking Medicine Technology:PGI Expands Manufacturing Capabilities At Mexico Plant 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 3Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 4Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 5Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 6Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 7Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 8European Laboratory Information System Market Report 2015: Germany holds a larger share of the laboratory information systems market 2European Laboratory Information System Market Report 2015: Germany holds a larger share of the laboratory information systems market 3
... Vista Partners announced today that it has updated coverage ... PRWP ) ("the Company") and maintains its twelve month target ... stated, "DAVANAT®, the Company,s lead product candidate, could potentially enhance ... Avastin® , while also reducing the side effect profile of ...
... Tenn. and MERCER ISLAND, Wash., Dec. 22, 2010 Renal ... to form the third largest provider of dialysis services in ...  The transaction – terms of which were not disclosed – ... 5,300 employees serving more than 19,000 patients in 260 locations ...
Cached Medicine Technology:Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Maintains Target Price of $2.10 2Renal Advantage and Liberty Dialysis Deal Completed 2Renal Advantage and Liberty Dialysis Deal Completed 3
(Date:3/31/2015)... (PRWEB) March 31, 2015 St. Joseph ... growing network of leading healthcare systems, major physician groups ... information for the benefit of patients. The health information ... that supports well coordinated care throughout the continuum of ... a long tradition of providing services to a broad ...
(Date:3/31/2015)... Juvent Sports ( http://www.juventsports.com ) recently ... show in Orlando. At the show, former LPGA golf ... was interviewed and she shared the life-changing physical improvements ... began integrating the Juvent Pro Micro-Impact Platform™ into her ... instrumental to her chronic back pain recovery that it ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 An individual’s ... most important ligaments in the leg providing stability, load ... their study at today’s Specialty Day meeting of the ... utilized MRI data to determine the potential for biologic ... currently understood about the healing of meniscus tears when ...
(Date:3/31/2015)... Bend, Indiana (PRWEB) March 31, 2015 ... Lee DeRose in Youngstown, Ohio in 1987. ... of the curve with not just customer satisfaction, ... has been added to the well-stocked arsenal of ... manufactured by American Green Technology® (AGT). The patented ...
(Date:3/31/2015)... Wis. (PRWEB) March 31, 2015 For ... patients and a faster return on their investment, ... composition analyzer at Obesity Medicine 2015, April 8-12 at ... busy weight loss centers and medical offices, Rice Lake’s ... a health assessment tool. Obesity Medicine 2015 delivers clinical ...
Breaking Medicine News(10 mins):Health News:St. Joseph Medical Center Joins Other Leading Healthcare Systems Participating in Greater Houston Healthconnect 2Health News:Former LPGA Tour Winner Maggie Will Discovers The Juvent Micro-Impact Platform as a Pain Relief Breakthrough and Performance Enhancer 2Health News:Former LPGA Tour Winner Maggie Will Discovers The Juvent Micro-Impact Platform as a Pain Relief Breakthrough and Performance Enhancer 3Health News:New Way to Evaluate Meniscus Tear Outcomes 2Health News:American Green Technology® Signs Exclusive Agreement to Distribute Health Risk Management System in Midwest 2Health News:Rice Lake Weighing Systems’ Body Composition Analyzer On Display at Obesity Medicine 2015 2
... (HealthDay News) -- A possible new risk factor for death ... The study of almost 1,300 people aged 65 and ... smoothly the heart rate returns to normal after a premature ... follow-up, abnormal heart rate turbulence was associated with an eight ...
... News) -- Americans living in parts of Appalachia and ... in their free time, according to federal government estimates ... likely to be physically active during leisure time are ... rates are 29.2 percent or greater for more than ...
... of regulatory T cells in the tumors of breast cancer ... long been unclear. Now new research at the ... regulatory T cells, whose job is to help mediate the ... and intensify the spread of breast cancer to distant organs ...
... is available in German . , ... and Efficiency in Health Care (IQWiG) published the results ... on coronary heart disease (CHD). The aim of the ... of high methodological quality that may be relevant for ...
... Hospital (MGH) study has identified a new role for an ... metastases. Published in the early edition of Proceedings ... how focal adhesion kinase (FAK) is involved in producing areas ... part of the premetastatic process and increases expression of ...
... in clinical trials expect that their personal information will ... Khaled El-Emam, Canada Research Chair in Electronic Health Information ... practices used to transfer and share sensitive files were ... Are Passwords Used to Protect Personal Health Information in ...
Cached Medicine News:Health News:Appalachia, the South Home to Least-Active Americans: CDC 2Health News:Key culprit identified in breast cancer metastasis 2Health News:DMP for coronary heart disease: Current guidelines indicate some need for revision 2Health News:DMP for coronary heart disease: Current guidelines indicate some need for revision 3Health News:Enzyme helps prepare lung tissue for metastatic development 2Health News:Study reveals security weaknesses in file-sharing methods used in clinical trials 2
... Cards. Insert the card and turn on the ... off after the programmed time. The Smart Card ... Simply provide your patient with the appropriate card ... the next visit.,The initial set of programmes covers ...
... ELPHA 4 Conti is a battery operated dual-channel ... of conditions described below. ELPHA 4 Conti also ... STRESS- and faecal incontinence ELPHA 4 Conti provokes ... the user can feel which muscles need exercising. ...
... template is designed for single-use ... the need for cleaning. The ... silicone molded over a metal ... placement while maintaining needle support ...
... The Reusable Template is designed ... a guidance system for prostate brachytherapy. ... on your software match the graphics ... with two pins protruding from lower ...
Medicine Products: